Anti-LCMV surface glycoprotein [M28], Human IgG1, kappa

Catalogue Number: AB05114-10.0-BT-ABA

Manufacturer:	Vector Laboratories, Inc (ABA)
Type:	Recombinant Monoclonal
Alias:	LCMV surface GP; lineage I Lassa fever virus; lineage I LASV; LASV; Pre-glycoprotein polyprotein GP complex; Pre-GP-C; Stable signal peptide; SSP; Glycoprotein G1; GP1; Glycoprotein G2; GP2; 18.5C-M28
Shipping Condition:	Blue Ice
Unit(s):	1 mg
Host name:	Human
Clone:	M28
Isotype:	IgG1
Immunogen:	The original antibody was generated by introducing two mutations (S32R and R55 insertion) into the sequence of the parent clone 18.5C (an isolate from a human survivor of Lassa fever).
Application:	ELISA, EM, NT, InVitroA, InVivoA

Overview
Datasheets

Additional Text

Purification

Purified

UniProt ID

P07399

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.

Application Notes

The original antibody (human IgG1) was generated and confirmed to specifically recognize the target via ELISA. A Fab version of it was generated and tested for neutralization. This antibody demonstrated potent in vitro neutralization (IC₅₀ ~ 0.51 µg/mL) and both prophylactic and therapeutic efficacy in a murine chronic LCMV model, with complete viral clearance and protection from weight loss. Furthermore, this antibody enabled high-resolution cryoEM of the LCMV GP trimer in both apo and Fab-bound states, defining a quaternary, pre-fusion-specific epitope (Moon-Walker et al., 2023; PMID: 36990092). In vitro, this antibody fully neutralized cell-free LCMV at 5 µg/mL and was used to demonstrate that ~50% of viral spread occurs via antibody-resistant, direct cell-to-cell nanotube transfer (Byford et al., 2024; PMID: 39578605).

AB05114-10.0-BT Datasheet

Price

£1,825.00

-

Quantity
Unit Size

Find out about delivery